In healthy dogs, sensory nerves transmit information about pain, temperature, and touch from the limbs to the brain. These signals help protect the body from injury by triggering appropriate responses to harmful stimuli. In dogs affected by Acral Mutilation Syndrome, sensory nerve dysfunction prevents normal pain perception in the paws and other extremities. Without the ability to feel discomfort, affected dogs may repeatedly lick, chew, bite, or traumatize their own feet, nails, toes, and skin without recognizing the damage they are causing.
Clinical signs of AMS typically become apparent during puppyhood or early adolescence. One of the earliest signs is excessive licking or chewing of the paws. As the condition progresses, affected dogs may develop ulcers, bleeding wounds, nail loss, toe deformities, infections, and severe tissue destruction. Some dogs may continue to traumatize affected areas despite significant injury. In advanced cases, chronic damage can lead to permanent disability, secondary infections, or the need for surgical intervention. Because affected dogs do not experience pain normally, injuries often go unnoticed until extensive damage has occurred.
The AMS DNA Health Test is designed to identify the specific genetic mutation associated with Acral Mutilation Syndrome. Testing is simple and non-invasive, requiring either a cheek swab or blood sample. The sample is analyzed in a specialized laboratory to determine the dog's genetic status. Since DNA remains unchanged throughout life, testing can be performed at any age, including in puppies before clinical signs develop.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the AMS mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is typically unaffected by the disorder. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a significantly increased likelihood of developing Acral Mutilation Syndrome.
Genetic testing for AMS provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed breeding decisions that help reduce the incidence of the disorder while preserving genetic diversity within the breed population. Avoiding the breeding of two carrier dogs significantly reduces the risk of producing affected puppies.
For dog owners, knowledge of a dog's genetic status allows for early monitoring and preventive management. Dogs identified as affected or at risk may require regular examination of the paws and limbs, protective measures to prevent self-trauma, and prompt veterinary treatment for wounds or infections. While there is currently no cure for the underlying nerve defect, early diagnosis and supportive care can help minimize complications and improve quality of life.
The Acral Mutilation Syndrome (AMS) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited sensory disorder in future generations. Through early detection and informed breeding decisions, breeders and owners can contribute to healthier dogs and improved long-term welfare.
